Condition
Locally Advanced
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 10 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownThoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerNCT06865339 · 2025-08-07
RECRUITINGAVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)NCT07038343 · 2025-06-04
RECRUITINGPACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLCNCT06102057 · 2024-07-01
RECRUITINGOmitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and ChemotherapyNCT06020430 · 2024-02-08
RECRUITINGInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerNCT05766800 · 2023-03-14
RECRUITINGTAD After Chemotherapy in Locally Advanced Breast CancerNCT05763641 · 2021-02-01
RECRUITINGThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29
RECRUITINGOpen Label Extension Study of Conatumumab and Ganitumab (AMG 479)NCT01327612 · 2011-03-03
COMPLETEDQUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsNCT00819169 · 2009-01-16
TERMINATEDA Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast CancerNCT00378313 · 2001-11-01
COMPLETEDCommon interventions
RadiotherapyRADIATION2AMG 479BIOLOGICAL1AMG 655BIOLOGICAL1AVZO-1418DRUG1BevacizumabBIOLOGICAL1CarboplatinDRUG1CemiplimabDRUG1ChemotherapyDRUG1Combination Agent 1DRUG1Combination Agent 2DRUG1ConatumumabBIOLOGICAL1CTV omitted or delineatedRADIATION1Experimental RadiotherapyRADIATION1FianlimabDRUG1GanitumabBIOLOGICAL1gemcitabine, epirubicin, paclitaxelDRUG1ImmunotherapyDRUG1Liposomal paclitaxelDRUG1Modified FOLFOX6DRUG1Nab-paclitaxelDRUG1pembrolizumabDRUG1PemetrexedDRUG1Platinum Doublet Chemotherapy (PDC)DRUG1rezatapoptDRUG1SerplulimabDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
RECRUITING7
COMPLETED2
TERMINATED1
Phase mix
PHASE28
PHASE13
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.